Daniel Reshef
About Daniel Reshef
Dr. Daniel Reshef (age 74) is an independent director of Two Hands Corporation, serving since May 8, 2025. He is a board‑certified physician with 25+ years in drug development, dual Israeli/U.S. citizenship, and advanced degrees (MPH and PhD in Epidemiology) from Johns Hopkins after graduating from Hebrew University and Hadassah Medical School in Jerusalem .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Hoffmann‑La Roche | Senior management positions in drug development | Not disclosed | Leadership across regulatory, medical affairs, drug safety ops; early–Phase IV development |
| Genentech | Senior management positions | Not disclosed | Clinical trials epidemiology; multi‑therapeutic area leadership |
| Bristol Myers Squibb | Senior management positions | Not disclosed | Early‑to‑late stage drug development oversight |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Major global pharmaceutical company (unnamed) | Therapeutic Area Global Head | Current | Extensive relationships with Israel medical research centers; regulatory and clinical leadership |
Board Governance
- Independence: Determined independent under NYSE and Canadian NI 58‑101 (along with Craig Marshak) .
- Committees: Audit Committee member; Audit Committee comprises Emil Assentato (Chair, not independent), Craig Marshak, and Daniel Reshef; majority independent .
- Audit Committee charter adopted: September 17, 2025 .
- Compensation/Nominating: No separate committees; full Board oversees these functions due to company size/maturity .
- Years of service on board: Since May 8, 2025 .
- Executive sessions/attendance: Not disclosed in proxy .
Fixed Compensation
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Annual retainer (cash) | — | — | — |
| Committee membership fees | — | — | — |
| Committee chair fees | — | — | — |
| Meeting fees | — | — | — |
| All other cash compensation | — | — | — |
Notes: Non‑employee directors (including Reshef) were appointed in 2025 and received no director compensation in 2022–2024 .
Performance Compensation
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Stock awards ($) | — | — | — |
| Option awards ($) | — | — | — |
| Non‑equity incentive ($) | — | — | — |
Outstanding awards and vesting (as of FY 2024):
- Option‑based awards: None (no options outstanding, no in‑the‑money value) .
- Share‑based awards: None (no unvested/vested share units) .
- Value vested/earned in year: None for options, share‑based, or non‑equity incentives .
Other Directorships & Interlocks
| Company | Role | Public Company? | Interlock with TWOH Ecosystem |
|---|---|---|---|
| None | N/A | No other reporting issuer directorships | None |
Expertise & Qualifications
- Board‑certified physician; MPH and PhD in Epidemiology (Johns Hopkins); MD (Hebrew University/Hadassah) .
- 25+ years in pharmaceutical R&D; deep experience in regulatory, medical affairs, drug safety operations, clinical trials epidemiology; leadership from Phase I–IV across multiple therapeutic areas .
- Current Therapeutic Area Global Head; strong Israel/global pharma relationships .
Equity Ownership
| Holder | Shares Beneficially Owned | Percent of Shares Outstanding |
|---|---|---|
| Daniel Reshef | — (no reported beneficial ownership) | — |
Reference base: 5,863,489,692 common shares outstanding as of October 14, 2025 .
Governance Assessment
-
Strengths:
- Independent director with deep life‑sciences expertise; adds risk oversight capability and scientific rigor to the Board .
- Audit Committee majority independent, charter adopted in 2025; formalized scope over financial reporting, controls, and auditor independence .
-
Risks/RED FLAGS:
- Audit Committee chaired by CEO (not independent), which weakens financial oversight independence and is atypical best practice. Majority independence helps, but chair role remains a governance concern .
- No compensation or nominating committee; full Board handles pay and nominations. Common in microcaps but elevates potential for conflicts and reduces specialized oversight .
- No disclosed director compensation framework or equity grants yet; combined with no stock ownership by Reshef, alignment relies on reputation rather than financial exposure to outcomes .
-
Conflicts/Related‑Party:
- Company discloses no related‑party transactions >$120,000 involving directors/officers, no indebtedness, and no selection arrangements with major shareholders/customers/suppliers—reducing conflict risk .
- None of the nominees/officers subject to bankruptcies, sanctions, or SEC/CFTC findings per disclosure—no disclosed legal red flags .
-
Attendance/Engagement:
- Board and Audit Committee each held one meeting in FY 2024; director‑specific attendance not disclosed and Reshef joined in 2025, so prior attendance data does not apply .
-
Ownership Alignment:
- No reported beneficial ownership for Reshef as of October 14, 2025; suggests limited direct financial alignment with shareholders until a director equity program is adopted .
RED FLAG: CEO chairs Audit Committee (not independent), contrary to typical best practice for robust financial oversight .
RED FLAG: Absence of compensation and nominating committees may impair independent oversight of pay and director selection .
Citations
Director roster with ages and “Director Since”; notes on Audit Committee membership.
Biographical details for Daniel Reshef (education, roles, expertise).
Director independence determination; statement of no other reporting issuer directorships; board meeting count for FY 2024.
Audit Committee composition, independence, chair designation, charter adoption, meeting count for FY 2024, responsibilities.
Disclosure that there is no compensation or nominating committee (full Board oversight).
Director compensation table 2022–2024 (non‑employee directors appointed in 2025; no comp); director awards tables show none; value vested tables show none.
Security ownership table (no reported beneficial ownership for Reshef; share count/percent context).
Related‑party, indebtedness, selection arrangements disclosures (none).
Outstanding shares and voting rights as of the Record Date.